Amphastar Pharmaceuticals, Inc. (AMPH)
| Market Cap | 806.46M -30.7% |
| Revenue (ttm) | 720.53M -1.4% |
| Net Income | 79.23M -44.1% |
| EPS | 1.67 -39.7% |
| Shares Out | 44.09M |
| PE Ratio | 11.01 |
| Forward PE | 5.87 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 722,237 |
| Open | 17.50 |
| Previous Close | 17.50 |
| Day's Range | 17.43 - 18.57 |
| 52-Week Range | 17.03 - 31.26 |
| Beta | 0.97 |
| Analysts | Hold |
| Price Target | 25.60 (+39.97%) |
| Earnings Date | May 7, 2026 |
About AMPH
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the preven... [Read more]
Financial Performance
In 2025, Amphastar Pharmaceuticals's revenue was $719.89 million, a decrease of -1.65% compared to the previous year's $731.97 million. Earnings were $98.09 million, a decrease of -38.51%.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for AMPH stock is "Hold." The 12-month stock price target is $25.6, which is an increase of 39.97% from the latest price.
News
Amphastar price target lowered to $21 from $25 at Piper Sandler
Piper Sandler lowered the firm’s price target on Amphastar (AMPH) to $21 from $25 and keeps a Neutral rating on the shares following quarterly results. The firm says that though…
Amphastar downgraded to Hold from Buy at Needham
Needham downgraded Amphastar (AMPH) to Hold from Buy.
Amphastar cut to Hold at Needham after ‘disappointing’ results
As previously reported, Needham downgraded Amphastar (AMPH) to Hold from Buy. The company reported top and bottom line misses for the second quarter in a row, with weakness coming from…
Amphastar Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew to $171.2M, driven by new launches and stable base business, though net income and margins declined due to pricing and product mix. BAQSIMI and Primatene MIST showed strong demand, while AMP-007's launch is expected to drive growth.
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026
Net revenues of $171.2 million for the three months ended March 31, 2026 GAAP net income of $6.4 million, or $0.14 per share, for the first quarter Adjusted non-GAAP net income of $19.5 million, or $0...
Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / May 6, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Opera...
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7, 2026
RANCHO CUCAMONGA, CA / ACCESS Newswire / April 30, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that the Company will release results for its first quarter of 2026, ended March...
Amphastar downgraded to Hold from Buy at Jefferies
Jefferies analyst Dennis Ding downgraded Amphastar (AMPH) to Hold from Buy with a price target of $22, down from $30. Despite what the firm calls an “inexpensive valuation,” it cites…
Amphastar Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference
Strong growth in 2025 was driven by Baqsimi and Primatene Mist, with new launches and a robust pipeline supporting mid to high single-digit revenue growth for 2026. Strategic product discontinuations and collaborations are improving margins and market reach, while disciplined business development and a solid balance sheet position the company for further expansion.
Amphastar price target lowered to $23 from $30 at Barclays
Barclays lowered the firm’s price target on Amphastar (AMPH) to $23 from $30 and keeps an Equal Weight rating on the shares. The firm says is encouraged by the company’s…
Amphastar Pharmaceuticals to Present at the 25th Annual Needham Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / April 6, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") announced today that Bill Peters, CFO, Tony Marrs, EVP of Regulato...
Amphastar Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference
Fiscal year results were broadly in line with expectations, with BAQSIMI and Primatene MIST driving growth despite competitive and pricing pressures. Pipeline launches, including ipratropium and future insulin products, are expected to support long-term growth, while operational efficiencies and stock buybacks remain key priorities.
Amphastar Pharmaceuticals to Present at the Barclays 28th Annual Global Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / March 4, 2026 / announced today that Bill Peters, CFO, and Dan Dischner, SVP of Corp. Communication, will be presenting at the Barclays 28th Annual Global Heal...
Amphastar price target lowered to $30 from $34 at Wells Fargo
Wells Fargo lowered the firm’s price target on Amphastar (AMPH) to $30 from $34 and keeps an Overweight rating on the shares. The firm thinks shares are weak on the…
Amphastar Pharmaceuticals Earnings Call Transcript: Q4 2025
2025 saw resilient growth in BAQSIMI and new FDA approvals, offset by legacy product declines and margin pressures. 2026 guidance calls for mid-to-high single-digit revenue growth, driven by new launches and pipeline expansion, with continued investment in R&D and manufacturing.
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025
Net revenues of $183.1 million and $719.9 million, respectively, for the three months and fiscal year ended December 31, 2025 GAAP net income of $24.4 million, or $0.51 per share and $98.1 million, or...
Amphastar gets FDA approval for Ipratropium Bromide HFA Inhalation Aerosol ANDA
Amphastar (AMPH) announced that the FDA has approved the company’s abbreviated new drug application, or ANDA, for Ipratropium Bromide HFA Inhalation Aerosol 17mcg/actuation. The FDA determined that Am...
Amphastar Announces FDA Approval for Ipratropium Bromide HFA
RANCHO CUCAMONGA, CA / ACCESS Newswire / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbre...
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 26, 2026
RANCHO CUCAMONGA, CA / ACCESS Newswire / February 20, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2025 ended December...
Amphastar Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
A fully integrated model and dual growth strategy drive a shift toward proprietary and biosimilar products, with significant R&D investment fueling a robust pipeline in oncology, ophthalmology, and endocrinology. Key growth is expected from Baqsimi, Primatene Mist, and upcoming launches, while strategic market exits and targeted acquisitions support profitability.
Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound
Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA / ACCESS Newswire / January 12, 2026 / Amphastar Pharmaceuticals, In...
Amphastar price target lowered to $30 from $31 at BofA
BofA analyst Pavan Patel lowered the firm’s price target on Amphastar (AMPH) to $30 from $31 and keeps a Neutral rating on the shares as the analyst took over coverage…
Amphastar Pharmaceuticals to Present at the J.P. Morgan 2026 Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / January 7, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at ...
Amphastar announces FDA approval for teriparatide injection
Amphastar (AMPH) Pharmaceuticals announced that the U.S. Food and Drug Administration has approved the Company’s Abbreviated New Drug Application for teriparatide injection, USP 560 mcg/2.24mL single-...
Amphastar Announces FDA Approval for Teriparatide Injection
RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbre...